. . . . . "1.9-3.7 hours"@en . . . . "124937-51-5"@en . " "@en . . . . "Yatendra Kumar, \"PROCESS FOR THE PREPARATION OF TOLTERODINE.\" U.S. Patent US20040249211, issued December 09, 2004."@en . . . . . . . . . . "Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days."@en . "Tolterodine"@en . . . . . . . . . . . . . "Take with food."@en . . . . . . . "Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder."@en . "For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)."@en . " "@en . . . . . . . "Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors."@en . . . . "Tolterodina"@en . . "(+)-Tolterodine"@en . "Humans and other mammals"@en . "investigational"@en . . . . . . . "(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresol"@en . . . . . . . "approved"@en . . "Approximately 96.3%."@en . . "Tolterodine"@en . . . . "Tolterodinum"@en . "* 113 \u00B1 26.7 L"@en . . .